IMVT-1401-3203: An Open-label Extension Study for Participants who
Completed Study IMVT-1401-3201 or Study IMVT-1401-3202 to Assess the Efficacy and Safety of Batoclimab for the Treatment of Thyroid Eye Disease (TED)10/06/2023 - 10/05/2026 (PI)
Immunovant Sciences, GmbH
IMVT-1401-3201: A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED)06/08/2023 - 06/07/2026 (PI)
Immunovant Sciences, GmbH